Search - tctmd.com

Displaying 201 - 220 of 254

Sort: Relevancy | Date

News Daily News

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

July 24, 2013

News Daily News

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

July 24, 2013

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

News Daily News

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

Caitlin E. Cox

May 13, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Yael L. Maxwell

March 09, 2013

News Daily News

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Yael L. Maxwell

March 09, 2013

News Daily News

ROCKET AF Analysis Looks at Stroke Risk After Stopping Anticoagulation

February 04, 2013

News Daily News

El ROCKET AF Analiza el Riesgo de ACV tras Interrumpir la Anticoagulación

February 04, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

Advertisement

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

Una Dosis Baja de Rivaroxaban Reduce los Episodios Trombóticos y Aumenta las Hemorragias tras un STEMI

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

ROCKET AF Analysis Looks at Stroke Risk After Stopping Anticoagulation

El ROCKET AF Analiza el Riesgo de ACV tras Interrumpir la Anticoagulación

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content